KU Weight Management Program

The KU Weight Management Program operates as part of The University of Kansas Health System in Kansas City, Kansas, delivering physician-supervised weight management services that integrate GLP-1 receptor agonist peptide therapies with structured lifestyle modification protocols. This university-affiliated program treats patients throughout Kansas via telehealth consultations, focusing on medically complex obesity cases and patients with concurrent type 2 diabetes who require coordinated metabolic care. The program's clinical model combines prescription peptide therapy with evidence-based behavioral interventions designed to address the physiological and lifestyle factors that contribute to weight regain.

Patients at the KU Weight Management Program have access to three FDA-approved GLP-1 medications: liraglutide (administered as a daily subcutaneous injection), semaglutide (weekly injection), and tirzepatide (weekly injection combining GLP-1 and GIP receptor agonism). Provider selection among these peptides depends on individual metabolic profiles, insurance coverage, diabetes status, and weight loss targets. Semaglutide and tirzepatide typically produce greater weight reduction compared to liraglutide, with tirzepatide demonstrating superior glycemic control in patients with diabetes. The clinical team monitors patients for common side effects including nausea, gastrointestinal changes, and injection site reactions, adjusting dosing schedules to optimize tolerance while maintaining therapeutic efficacy. Patients receiving these peptides undergo regular metabolic assessments to track HbA1c levels, lipid panels, and body composition changes throughout treatment.

The program's physicians and clinical staff hold credentials through The University of Kansas Health System and follow treatment protocols informed by current obesity medicine research and American Board of Obesity Medicine guidelines. Providers conduct comprehensive metabolic evaluations before initiating peptide therapy, screening for contraindications such as personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and severe gastroparesis. The clinical approach emphasizes patient education on the mechanisms of GLP-1 receptor agonists, including appetite regulation through hypothalamic pathways, delayed gastric emptying, and improved insulin secretion. Patients learn to recognize appropriate hunger and satiety cues as peptide therapy modulates these signals, which supports sustainable eating pattern changes beyond medication use.

Telehealth consultations allow Kansas residents to participate in the program without traveling to Kansas City for routine follow-up appointments, though initial evaluations may require in-person assessment depending on medical complexity. During virtual visits, providers review food logs, discuss barriers to physical activity implementation, and adjust peptide dosing based on weight trends and side effect profiles. The program incorporates structured guidance on incorporating morning movement routines, stress management techniques that reduce cortisol-driven eating behaviors, and strategies for increasing vegetable intake to improve satiety on reduced-calorie meal plans. Patients receive specific exercise recommendations calibrated to current fitness levels, with progressive increases in duration and intensity as weight loss improves cardiovascular capacity and joint loading tolerance.

The KU Weight Management Program distinguishes itself through its university health system infrastructure, which enables coordination with endocrinology, cardiology, and behavioral health specialists when patients require multidisciplinary management of obesity-related comorbidities. This integration proves particularly valuable for patients with uncontrolled diabetes, hypertension, or sleep apnea that improves with weight reduction. The program's meal replacement component provides patients with structured nutrition options during the initial weight loss phase, though providers transition patients toward whole-food eating patterns that emphasize protein intake, fiber-rich vegetables, and metabolic flexibility. Patients gain access to registered dietitians who provide individualized macronutrient targets and teach practical meal planning skills that support weight maintenance after peptide therapy concludes or transitions to lower maintenance doses.